Galderma stock faces CFO transition before December board vote
Published on 11/12/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGovernance transition sets next catalyst
- Luigi La Corte will leave Galderma after a transition period supporting business continuity.
- Shareholders will vote on Rosalind Brewer and Petra Rumpf at the December 3 extraordinary meeting.
- The board wants to raise its maximum size from 10 to 11 members.
Galderma announced on November 2, 2026, that Chief Financial Officer Luigi La Corte will leave the dermatology company to pursue a significant new opportunity. The announcement also set a December shareholder vote on proposed board appointments and other governance changes.
According to the Galderma announcement, La Corte will continue to fulfil his responsibilities during the transition period. The company said this arrangement is intended to support business continuity and a smooth handover, while further details on succession arrangements and the transition timeline will follow.
Board changes go to shareholders
Galderma's board is proposing Rosalind Brewer and Petra Rumpf as new directors. The company describes both candidates as bringing leadership and governance experience across consumer-facing businesses, healthcare, medtech and life sciences.
Sherilyn McCoy is set to step down from the board after seven years because of conflicting obligations. The proposals would increase the board's maximum size from 10 to 11 members and elect Brewer and Rumpf until the conclusion of the next Annual General Meeting. Brewer is also proposed for individual election to the Compensation Committee.
The virtual Extraordinary General Meeting will take place on Thursday, December 3, 2026, at 14:00 CET. For investors, the meeting is the next defined governance milestone, while the CFO succession remains a separate execution issue because the company has not yet provided further transition details.
April vote adds governance context
The earlier Annual General Meeting in Zug on April 22, 2026, approved all proposals put forward by the board. The company's AGM release said shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share, elected Harry Kirsch as an independent director and elected Samuel du Retail and Delphine Viguier-Hovasse as non-independent L'Oreal representatives. The 2025 annual financial statements, non-financial report and compensation report also received approval.
Galderma stock traded at 213.00 euros on Lang & Schwarz at 12:16 CET on Thursday, November 12, 2026.
Galderma Group AG
- Company: Galderma Group AG
- ISIN: CH1335392721
- Stock ticker: GALD
- Home exchange: SIX Swiss Exchange
- Lang & Schwarz quote: 213.00 euros at 12:16 CET on November 12, 2026
- Approved gross dividend: CHF 0.35 per dividend-bearing share
The Swiss market backdrop can be followed in current SMI market coverage.
More news and analyses on Galderma stock.
